In conclusion, our data suggest that detection of MDM2 amplicons could be a useful tool in uterine sarcoma pathology and implicate MDM2 as a potential therapeutic target in HGESS‐BCOR. The gene discussed is MDM2; the disease is uterine corpus sarcoma.